LOGIN  |  REGISTER
Terns Pharmaceuticals
Compass Therapeutics

Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024

August 29, 2024 | Last Trade: US$46.02 0.51 -1.10

TOPLINE SUMMARY

• Inari Medical, Inc. announced that data from the PEERLESS trial will be presented by Dr.
• Wissam Jaber during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C.
• The presentation will take place on October 29th.
• The PEERLESS trial is a prospective, randomized controlled trial (“RCT”) comparing the outcomes.

IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th.

The PEERLESS trial is a prospective, randomized controlled trial (“RCT”) comparing the outcomes of patients with intermediate-risk pulmonary embolism (“PE”) treated with the FlowTriever system versus catheter-directed thrombolysis. The primary endpoint is a win-ratio analysis of important clinical and hospital resource utilization outcomes. This study will provide critical information to clinicians on the optimal treatment for PE patients.

“PEERLESS is the first RCT directly comparing FlowTriever to a historical treatment option for PE and is the first of several RCTs that Inari is bringing to the VTE space,” said Dr. Thomas Tu, Inari’s Chief Medical Officer. “Patients and physicians deserve high-quality clinical evidence to inform treatment choices and we are thrilled to see this study be presented at TCT.”

About Inari Medical, Inc.

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and four other targeted disease states. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.

Investor Contact:
Marissa Bych
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB